Stoke Therapeutics Inc [STOK] stock is trading at $24.14, up 5.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The STOK shares have gain 5.41% over the last week, with a monthly amount glided 25.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on July 18, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $30. Previously, Chardan Capital Markets started tracking the stock with Buy rating on December 20, 2024, and set its price target to $24. TD Cowen upgraded its rating to a Outperform. TD Cowen downgraded its rating to Market Perform for this stock on July 25, 2023. In a note dated May 01, 2023, BofA Securities upgraded an Neutral rating on this stock and boosted its target price from $9 to $12.
Stoke Therapeutics Inc [STOK] stock has fluctuated between $5.35 and $24.60 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $24.14 at the most recent close of the market. An investor can expect a potential return of 15.99% based on the average STOK price forecast.
Analyzing the STOK fundamentals
Stoke Therapeutics Inc [NASDAQ:STOK] reported sales of 199.89M for the trailing twelve months, which represents a growth of 186.01%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.18 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.31 points at the first support level, and at 22.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.66, and for the 2nd resistance point, it is at 25.17.
Ratios To Look Out For
For context, Stoke Therapeutics Inc’s Current Ratio is 6.98. On the other hand, the Quick Ratio is 6.98, and the Cash Ratio is 2.62. Considering the valuation of this stock, the price to sales ratio is 6.62, the price to book ratio is 3.94 and price to earnings (TTM) ratio is 28.57.
Transactions by insiders
Recent insider trading involved Ticho Barry, CHIEF MEDICAL OFFICER, that happened on Sep 02 ’25 when 5501.0 shares were sold. Director, Kaye Edward M. MD completed a deal on Sep 03 ’25 to sell 45996.0 shares. Meanwhile, Director Kaye Edward M. MD sold 14860.0 shares on Sep 02 ’25.
